GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hangzhou Jiuyuan Genetic Biopharmaceutical Co 2566.HK · HKD

N/A · HKEX · 🇭🇰 Hong Kong

Compare

4.47

-2.61%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥1.31bn

FY2021FY2025

Net income

CN¥138.4m

FY2021FY2025

Free cash flow

CN¥150.2m

FY2021FY2025

Shareholders' equity

CN¥1.65bn

FY2021FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021
RevenueCN¥1.31bnCN¥1.16bnCN¥1.10bnCN¥957.4mCN¥1.31bn
Gross profitCN¥1.05bnCN¥920.2mCN¥842.8mCN¥726.8mCN¥950.4m
Research and developmentCN¥123.7mCN¥92.6mCN¥108.7mCN¥134.7mCN¥132.6m
Operating incomeCN¥167.2mCN¥149.5mCN¥122.8mCN¥51.4mCN¥136.0m
Net incomeCN¥138.4mCN¥117.9mCN¥101.9mCN¥50.9mCN¥119.4m
Diluted earnings per share0.560.480.420.210.50

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Total assetsCN¥2.12bnCN¥1.64bnCN¥1.11bnCN¥1.03bnCN¥1.18bn
Cash and short-term investmentsCN¥650.8mCN¥520.1mCN¥107.3mCN¥98.7m—
Total liabilitiesCN¥469.7mCN¥344.6mCN¥348.6mCN¥380.6mCN¥465.1m
DebtCN¥112.7mCN¥33.0mCN¥30.2mCN¥67.0mCN¥45.8m
Shareholders' equityCN¥1.65bnCN¥1.29bnCN¥763.9mCN¥651.8mCN¥718.1m
Shares outstanding245m245m241m241m241m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Cash from operationsCN¥254.8mCN¥80.6mCN¥115.5mCN¥19.2mCN¥67.5m
Capital spending−CN¥104.6m−CN¥67.9m−CN¥40.0m−CN¥50.2m−CN¥62.9m
Free cash flowCN¥150.2mCN¥12.7mCN¥75.5m−CN¥31.0mCN¥4.6m
Dividends paid−CN¥13.7m——−CN¥10.2m—

Latest quarters

By quarter end

Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023
RevenueCN¥667.5mCN¥638.8mCN¥567.3mCN¥597.6mCN¥530.9mCN¥663.4m
Gross profitCN¥528.8mCN¥525.2mCN¥460.4mCN¥459.9mCN¥392.3mCN¥529.6m
Operating incomeCN¥60.2mCN¥107.0mCN¥35.9mCN¥113.7mCN¥27.4mCN¥111.8m
Net incomeCN¥48.2mCN¥90.2mCN¥28.3mCN¥89.6mCN¥19.9mCN¥96.4m
Diluted earnings per share0.200.370.120.370.080.39
Cash from operations—CN¥12.0mCN¥80.0m−CN¥10.0mCN¥115.0m−CN¥13.0m
Capital spending—−CN¥46.0m−CN¥67.0m−CN¥27.0m−CN¥39.0m−CN¥15.0m
Free cash flow—−CN¥34.0mCN¥13.0m−CN¥37.0mCN¥76.0m−CN¥28.0m
Total assetsCN¥2.12bnCN¥2.04bnCN¥1.64bnCN¥1.22bn——
Cash and short-term investmentsCN¥650.8mCN¥586.9mCN¥520.1mCN¥100.5m——
DebtCN¥112.7mCN¥94.0mCN¥33.0mCN¥27.3m——
Shareholders' equityCN¥1.65bnCN¥1.60bnCN¥1.29bnCN¥856.1m——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue11.5%——
Operating income48.1%——
Net income39.5%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin79.9%78.3%——

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings11.611.9
Price to sales1.21.2

Dividends and splits

Per share, in the currency the company pays

Paid for 1 years. Last went ex-dividend on 13 Jun 2025.

FY2025
Paid in the year0.061

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.